A Study of Remternetug (LY3372993) in Healthy Participants
Completed · Phase 1 · NCT07056309
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $3.8M
- U.S. investigators named
- 3
- Sites paid
- 3
- Planned or actual enrollment
- 72
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Remternetug (Test) (drug), Remternetug (Reference) (drug)
- Dates
- Started 2025-06-24; completion 2025-12-15
- Results posted
- Not yet
The main purpose of this study is to evaluate to different formulations of remternetug after single subcutaneous (SC) administration with either an autoinjector (AI) or a prefilled syringe (PFS). The study will look at the amount of remternetug that gets into the bloodstream and how long it takes the body to get rid of the remternetug when given as two different formulations. Participation in the study will last approximately 155 days.
From ClinicalTrials.gov, last updated 2026-01-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $3.8M in research payments for this study in 2025 (9 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Hugh A. Coleman, DO Family Medicine · Daytona Beach, FL
- Donald W. Burkindine, DO Geriatric Medicine · Marshfield, MO
- Gene W. Voskuhl, MD Infectious Disease · Sherman, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $1.3M
- Covance Clinical Research LP Dallas $1.3M
- Bio Kinetic Clinical Applications LLC $1.2M
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.